Wockhardt
Wockhardt Limited, a prominent player in the global pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1960, the company has established a strong presence in key operational regions, including the United States, Europe, and emerging markets. Wockhardt is renowned for its innovative approach to healthcare, focusing on biotechnology, generics, and specialty pharmaceuticals. The company’s core products encompass a diverse range of therapeutic areas, including antibiotics, vaccines, and biopharmaceuticals, distinguished by their commitment to quality and research-driven development. Wockhardt has achieved notable milestones, such as receiving multiple FDA approvals and expanding its manufacturing capabilities across the globe. With a robust market position, Wockhardt continues to contribute significantly to the healthcare landscape, driven by its dedication to improving patient outcomes and advancing medical science.
DitchCarbon Score
How does Wockhardt's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wockhardt's score of 40 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wockhardt's reported carbon emissions
In 2024, Wockhardt reported total carbon emissions of approximately 10052280 kg CO2e for Scope 1 and 55818850 kg CO2e for Scope 2, with an additional 308710 kg CO2e from Scope 3 emissions. This data reflects a significant operational footprint, with Scope 2 emissions being the most substantial contributor. Comparatively, in 2023, Wockhardt's emissions were higher, with Scope 1 at 19167000 kg CO2e and Scope 2 at 112712000 kg CO2e, indicating a potential reduction in emissions in 2024. In 2022, the company reported 32846000 kg CO2e for Scope 1 and 143853000 kg CO2e for Scope 2, further highlighting a downward trend in emissions over the years. Wockhardt has set ambitious climate commitments, aiming for a 50% reduction in absolute emissions for both Scope 1 and Scope 2 by 2030, starting from 2021 levels. This target demonstrates the company's proactive approach to mitigating its carbon footprint and aligns with industry standards for climate action. The emissions data is not cascaded from any parent organization, indicating that Wockhardt Limited independently reports its carbon emissions and climate initiatives. Overall, Wockhardt's commitment to reducing emissions reflects a growing awareness and responsibility towards climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 32,846,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 143,853,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wockhardt is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
